NYSE - Nasdaq Real Time Price USD

Bristol-Myers Squibb Company (BMY)

44.85

+0.15

(+0.34%)

At close: April 26 at 4:00 PM EDT

45.10

+0.25

(+0.56%)

Pre-Market: 9:16 AM EDT

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a multi-year strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system.

PR Newswire 3 hours ago

BMY
+0.34%
CELG-RT
Repertoire pivot pays dividends with Bristol Myers deal

The alliance validates the new direction pursued by Repertoire, a startup that cut staff and switched CEOs in 2022 after research on personalized cell therapies disappointed.

BioPharma Dive 7 hours ago

CELG-RT
Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Bristol-Myers Squibb ( NYSE:BMY ) First Quarter 2024 Results Key Financial Results Revenue: US$11.9b (up 4.7% from 1Q...

Simply Wall St. yesterday

BMY
+0.34%
CELG-RT
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

Zacks 3 days ago

VRTX

INCY

CELG-RT
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....

Business Wire 3 days ago

BMY
+0.34%
CELG-RT
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)

A Strategic SWOT Insight into Bristol-Myers Squibb's Financials and Future

GuruFocus.com 3 days ago

CELG-RT
Q1 2024 Bristol-Myers Squibb Co Earnings Call

Q1 2024 Bristol-Myers Squibb Co Earnings Call

Thomson Reuters StreetEvents 3 days ago

CELG-RT
Bristol Myers Squibb stock tumbles on cost-cutting initiative

Bristol Myers Squibb (BMY) shares are trading lower Thursday afternoon following the pharmaceutical company's announcement of several cost-cutting initiatives. Among the measures were workforce reductions and the termination of approximately 12 drug development programs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith.

Yahoo Finance Video 3 days ago

BMY
+0.34%
CELG-RT
AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.

Investor's Business Daily 3 days ago

AZN
+0.19%
SNY

CELG-RT
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.

Zacks 3 days ago

BIIB
+3.18%
INCY

CELG-RT
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions

Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted first-quarter revenues of $11.9 billion, beating the consensus of $11.5 billion, an increase of 5% year-over-year, or 6% when adjusted for foreign exchange impacts, primarily driven by Eliquis, Reblozyl, and Opdualag, partially offset by Opdivo and Revlimid. Growth Portfolio worldwide revenues increased to $4.8 billion, up 8% or 11% when adjusted for foreign exchange impacts. This increase was primarily driven by higher demand for Reblozyl, O

Benzinga 3 days ago

CELG-RT
Update: Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall

Update: Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall

PREMIUM
MT Newswires 3 days ago

CELG-RT
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 3 days ago

CELG-RT
Why Bristol Myers Squibb Stock Is Sinking Today

Investors didn't like the biopharmaceutical company's updated guidance.

Motley Fool 3 days ago

CELG-RT
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.

Zacks 3 days ago

CELG-RT
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that the company has enough growth drivers in the near term.

The Wall Street Journal 3 days ago

REGN

PFE
+0.55%
BMY
+0.34%
Bristol-Myers Squibb to Cut 2,200 Jobs as Part of $1.5 Billion Cost-Cutting Effort

Bristol-Myers Squibb will shed 2,200 employees this year as part of a cost-cutting effort to save $1.5 billion by the end of 2025. Chief Finance Officer David Elkins said that the job cuts are part of an effort to become more agile, and aim at "removing layers of management so decisions get made more quickly.” Company executives said the plan is to reinvest in the most promising drug-development programs that are most likely to produce high returns.

The Wall Street Journal 3 days ago

BMY
+0.34%
CELG-RT
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript

BMY earnings call for the period ending March 31, 2024.

Motley Fool 3 days ago

CELG-RT
Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts

The pharmaceutical company is implementing an initiative to cut costs by $1.5 billion by 2025 that will include about 2,200 job cuts.

Barrons.com 3 days ago

CELG-RT
Is Bristol Myers Squibb Stock a Millionaire Maker?

Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.

Motley Fool 3 days ago

CELG-RT

^GSPC

Performance Overview

Return	BMY	S&P 500
YTD	-10.55%	+6.92%
1-Year	-33.41%	+25.26%
3-Year	-24.59%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bristol-Myers Squibb Company (BMY)

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

Repertoire pivot pays dividends with Bristol Myers deal

Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)

Q1 2024 Bristol-Myers Squibb Co Earnings Call

Bristol Myers Squibb stock tumbles on cost-cutting initiative

AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions

Update: Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Why Bristol Myers Squibb Stock Is Sinking Today

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma

Bristol-Myers Squibb to Cut 2,200 Jobs as Part of $1.5 Billion Cost-Cutting Effort

Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts

Is Bristol Myers Squibb Stock a Millionaire Maker?

Performance Overview